Attention Hyperactivity Disorder

Attention Hyperactivity Disorder is the most common neuropsychiatric disorder among children and adolescents (affecting about 3 to 5% of this age range). The major symptoms of ADHD are attention problems, hyperactivity and impulsivity. The condition persists during adult age in about 15% of cases 

The most common prescribed drugs to treat ADH are psychostimulant (Methylphenidate, Amphetamine) and non-stimulant noradrenaline reuptake inhibitors (Atomoxetine).

A major objective of drug discovery targeting ADHD is developing new drugs with less undesirable side effects and better efficacy.

In vivo models of ADHD

  • Key-Obs, our preferred partner expert in developing in vivo models of neurological disorders, has developed 3 in vivo models of Attention Deficit Hyperactivity Disorders.
    • Impulsivity – Delayed discounting task
    • Attention – Two-choices visual discrimination task (2-CVDT)
    • Hyperactivity – Open-field test in spontaneously hypertensive rats (SHR)

Watch the following 30 min webinar presented by our expert Jean-Charles Bizot to understand more how these 3 models operate:

Are you currently working on compounds targeting Attention Deficit Hyperactivity Disorders?

Please contact us for any additional information and we will gladly come back to you. We can also set up a dedicated meeting between you and our experts to discuss our CRO services and your research needs.

Jean-Charles BIZOT, PhD
CEO & Behavioral Pharmacologist
KEY-OBS
Fabrice TROVERO,PhD
GM & Behavioral Pharmacologist
KEY-OBS